Program
ONO-1110
A development code.
Its studies are mostly in Neuralgia, Postherpetic · Phobia, Social · Depressive Disorder, Major · Fibromyalgia · Cystitis, Interstitial, led by Ono Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceutical | 50 open or running | phase 2since Nov 24, 2024 | Nov 24, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2024First study: phase 2 study in Neuralgia, PostherpeticFirst studyNCT06708416 · 142 enrolled · Japan
- Dec 22, 20242 phase 2 studiesNCT06752603, NCT06752590
- Jan 19, 20252 phase 2 studiesNCT06792136, NCT06805565
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06805565Phobia, Social · Japan | 2 | Completed | May 25, 2026 | 115 |
| NCT06792136Depressive Disorder, Major · Japan | 2 | Completed | Apr 9, 2026 | 103 |
| NCT06752603Hunner Type Interstitial Cystitis · Japan | 2 | Completed | Jun 12, 2026 | 57 |
| NCT06752590Fibromyalgia · Japan | 2 | Completed | May 30, 2026 | 175 |
| NCT06708416Neuralgia, Postherpetic · Japan | 2 | Completed | May 11, 2026 | 142 |
How it is read
Names in the registry
- “ONO-1110”, 5 entries
Codes read as this program: ONO1110.
Conditions, from the studies’ own filings
- Neuralgia, Postherpetic, 1 study
- Phobia, Social, 1 study
- Depressive Disorder, Major, 1 study
- Fibromyalgia, 1 study
- Cystitis, Interstitial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.